Viridian Therapeutics Aktie News & Pressemeldungen

Noticias de Eulerpool Viridian Therapeutics

17/12/2024, 18:21:58

Durchbruch in der Behandlung von Schilddrüsenaugenerkrankungen: Viridian Therapeutics überzeugt mit neuesten Studiendaten

17/12/2024, 18:34:24

Viridian Therapeutics glänzt mit bahnbrechenden Ergebnissen in Phase-III-Studie

Viridian Therapeutics Noticias de Acciones

Viridian Therapeutics es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Viridian Therapeutics.

5 de junio ·
Yahoo
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 de mayo ·
Yahoo
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
20 de mayo ·
Yahoo
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
6 de mayo ·
Yahoo
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
2 de mayo ·
Yahoo
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 de abril ·
Yahoo
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
2 de marzo ·
SeekingAlpha
Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window
8 de enero ·
Yahoo
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
19 de diciembre ·
SeekingAlpha
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
18 de diciembre ·
SeekingAlpha
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Viridian Therapeutics Noticias de la acción

Viridian Therapeutics publica regularmente en la página web de la empresa noticias relevantes para los inversores.

Reconoce acciones infravaloradas de un vistazo.

Suscripción por 2 € / mes